BenevolentAI is live · custom pricing · last verified 24 Oct 2026 · viability healthy
BenevolentAI
BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.
BenevolentAI's decade-deep knowledge graph and curated ontologies remain the real asset here, and Qor extends that intelligence from bench scientists to strategic decision makers. It fits large biopharma R&D organisations that already have data science capacity and are prepared to work inside a partnership model with real onboarding. If you need a plug-and-play, low-commitment research tool, look at Recursion Pharmaceuticals or Schrödinger instead. The public site is deliberately sparse — it publishes no specifications and routes you to a contact form — so confirm scope and terms in writing before you plan around them.
Verdict generatedVerified 6d ago · liveness 74/100 · cite: rightaichoice.com/tools/benevolentai
- Large pharmaceutical R&D teams
- Life science executives using Qor for strategic intelligence
- Biopharma consultancies running AI-assisted client engagements
- Computational biology groups with data-integration capacity
- General-purpose AI buyers outside life sciences
- Teams without resources for custom data integration
- Small labs or academic groups needing a low-commitment entry point
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip BenevolentAI if you want a self-serve research tool you can trial in an afternoon without committing internal engineering time to data integration.
Onboarding and custom data integration are part of deployment, so budget internal engineering and curation time from day one, not just the licence
BenevolentAI sells through a contact form with no published rates, so treat it as an enterprise partnership line item rather than a subscription you expense. That puts it alongside other discovery-stage platforms sold to large biopharma, and well above per-seat research tools. If your budget is per-seat software, this is not the right shape of purchase.
In short
BenevolentAI — BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams. Best for Large pharmaceutical R&D teams, Life science executives using Qor for strategic intelligence, Biopharma consultancies running AI-assisted client engagements. Pricing is on request (custom quotes).
No head-to-head comparison for BenevolentAI yet — the alternatives below are the closest matches we list.
What is BenevolentAI?
BenevolentAI — BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams. Best for Large pharmaceutical R&D teams, Life science executives using Qor for strategic intelligence, Biopharma consultancies running AI-assisted client engagements. Pricing is on request (custom quotes).
BenevolentAI is a life science intelligence company that applies AI and machine learning to drug discovery. The platform is built on a decade of investment in a proprietary biomedical knowledge graph and curated ontologies, and it serves biopharma researchers and executives who need evidence-backed decisions across target identification, hypothesis generation and drug repurposing. Because the graph integrates biomedical data and links diseases, genes and compounds, you can traverse relationships that are not visible in any single dataset. The core of the product is that knowledge graph, combined with AI and machine learning models tuned to drug discovery data. The vendor's own framing is that it brings together science and technology teams to "push AI and machine learning to new limits," building on the graph and its proprietary ontologies so scientists and executives can use AI in their work "with confidence and precision." In practice that means hypothesis generation with the underlying evidence attached rather than a bare model output, multi-omics integration for druggability assessment, and exploration of disease-gene-compound relationships. Alongside the core platform, BenevolentAI offers Qor, described on the site as "an always-on strategic function for biopharma decision makers and life science consultancies," powered by the same BenevolentAI technology. BenevolentAI is registered at 9 rue de Bitbourg, L-1273 Luxembourg (R.C.S. Luxembourg B288631). The public site is thin on commercial detail: it funnels interested buyers to a contact form rather than publishing specifications or terms, so treat any figure you see elsewhere as unverified until the vendor confirms it in writing.
Key features
- Proprietary biomedical knowledge graph built over a decade
- Curated biomedical ontologies structuring the graph
- AI and machine learning models tuned to drug discovery data
- Target identification via knowledge graph traversal
- Drug repurposing discovery through indirect data connections
- Evidence-backed hypothesis generation
- Multi-omics integration for druggability assessment
- Disease-gene-compound relationship exploration
- Life science intelligence interface for scientists and executives
- Qor: always-on strategic function for biopharma decision makers
- Qor support for life science consultancy engagements
Behind the verdict
BenevolentAI's pitch rests on something you can actually evaluate: a biomedical knowledge graph that the company says it has spent a decade building, plus proprietary ontologies that structure how diseases, genes and compounds connect. That matters because most AI drug discovery claims are hard to separate from each other. A curated graph is a data asset — it either has the coverage and the ontology quality your therapeutic area needs, or it doesn't — and that is a testable question you can put to the vendor in a pilot. The strongest functional claims on the site are specific: target identification through graph traversal, drug repurposing through indirect connections between datasets, evidence-backed hypothesis generation, and multi-omics integration for druggability assessment. Repurposing is where a graph genuinely earns its keep. If a compound's mechanism touches a pathway you'd never search for from the disease side, only an integrated graph surfaces it. Ask for a worked example in your own indication before you commit. Qor is the strategic layer — an "always-on strategic function for biopharma decision makers and life science consultancies," running on the same underlying technology. That framing tells you who the buyer is. This is not a tool a single researcher self-serves into. It is sold to people making portfolio, partnering and strategy calls, and to consultancies structuring client engagements around graph-derived evidence. Be clear-eyed about what you are taking on. Deployment means significant onboarding and custom data integration, so budget dedicated internal resource, not just a licence. The graph and its models are proprietary, so you cannot audit or reimplement the reasoning behind an output — you are trusting the vendor's curation and evaluation. And the platform has no application outside biopharma R&D and strategy work; it is not a general-purpose AI product and shouldn't be bought as one. One more caveat on this page: the material captured in this research pass is the vendor's marketing homepage. It carries no technical documentation, no release history and no commercial terms. That is a limit on what we can verify, not a statement about what the vendor does or doesn't publish — so ask directly for the documentation, validation evidence and terms you need.
Models under the hood
as of 2026-10-23
Limitations
- BenevolentAI is an enterprise-scale platform, and deployment involves significant onboarding and custom data integration — you need dedicated internal resource, not just a licence.
- The knowledge graph and its models are proprietary, so you cannot audit or reimplement the reasoning behind an output; you rely on the vendor's curation.
- The public homepage captured in this research pass carries no technical documentation, validation detail or commercial terms, so specifications and costs cannot be verified from these sources — confirm them with the vendor directly.
- The product is purpose-built for life sciences and has no applicability outside biopharma R&D and strategy work.
as of 2026-10-19
Researching BenevolentAI? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Is BenevolentAI still active?
BenevolentAI is live · custom pricing · last verified 24 Oct 2026 · viability healthy.
Viability score
How well maintained and how widely used is BenevolentAI? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →What do users say about BenevolentAI?
What people actually say about BenevolentAI — is it worth it?
We scanned public community sources for BenevolentAI on Aug 28, 2026 and could not establish that the discussion we found is about this tool rather than something else sharing its name. Our own analysis of that scan says the posts were off-subject. Rather than publish a sentiment score built on the wrong subject, we publish nothing here and re-run the scan.
How we verified this
Every listed fact about BenevolentAI— pricing, features, links, status — is re-read from the vendor's own pages by our verification pipeline and each change is logged with a date; the last pass ran on 24 Oct 2026. Pages mix model-assisted synthesis with human review; see how we verify.
Verification history
We have re-verified BenevolentAI 21 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — changed SSL certificate
- — changed switching out, pricing fit, description, our verdict, features, who should skip it, hidden costs, limitations, setup time, switching in
- — changed SSL certificate
- — changed switching out, pricing fit, features, who should skip it, limitations, switching in, hidden costs, description, summary, who it suits, use cases, setup time, our verdict
- — changed pricing page
- — changed features, summary, who it suits, who should skip it
Showing the 6 most recent of 21 verification passes.
Free to cite with attribution — this page re-verifies continuously.
How much does BenevolentAI cost in 2026?
BenevolentAI: Pricing is on request (custom quotes). Pricing last verified 24 Oct 2026.
Where the pricing makes sense
The company stage and team size where BenevolentAI's pricing actually pencils out — and where peers do it cheaper.
BenevolentAI sells through a contact form with no published rates, so treat it as an enterprise partnership line item rather than a subscription you expense. That puts it alongside other discovery-stage platforms sold to large biopharma, and well above per-seat research tools. If your budget is per-seat software, this is not the right shape of purchase.
Has BenevolentAI's pricing changed?
No plan price for BenevolentAI has moved since we began logging in Aug 2026; the pricing page is re-read on every verification pass.
Who should pick BenevolentAI?
Pick BenevolentAI if you are Large pharmaceutical R&D teams, Life science executives using Qor for strategic intelligence, Biopharma consultancies running AI-assisted client engagements, Computational biology groups with data-integration capacity.
Look elsewhere if you are General-purpose AI buyers outside life sciences, Teams without resources for custom data integration, Small labs or academic groups needing a low-commitment entry point.
Skip it if Skip BenevolentAI if you want a self-serve research tool you can trial in an afternoon without committing internal engineering time to data integration.
GeneratedReal-world workflow fit
Concrete scenarios for the personas BenevolentAI actually fits — and what changes day-one when you adopt it.
You have a disease of interest with thin genetic support and want candidate targets you haven't already pursued. You traverse the knowledge graph from the disease node into genes and compounds, then pull the supporting evidence for each association.
Outcome: A shortlist of target-disease associations with traceable evidence you can take into a triage meeting, rather than a single opaque model score.
A compound is stalled in one indication. You use indirect graph connections to look for mechanisms linking it to other diseases, then check druggability with integrated multi-omics context.
Outcome: A documented set of repurposing hypotheses with the graph path behind each one, ready for the portfolio review.
You need a standing strategic read on a therapeutic area or partnering opportunity and use Qor as the always-on intelligence layer behind that call.
Outcome: Strategic recommendations grounded in the same graph evidence the scientific team uses, so the executive view and the bench view stay aligned.
Use cases
- Identify novel target-disease associations by traversing the knowledge graph
- Prioritise compounds for a target using integrated chemical and omics data
- Discover repurposing opportunities through indirect graph connections
- Generate evidence-backed hypotheses for rare disease mechanisms
- Benchmark target druggability using integrated multi-omics features
- Trace unexpected biomarker relationships across literature and clinical data
- Support portfolio and partnering decisions through Qor strategic intelligence
- Structure a consultancy client engagement around graph-derived evidence
Setup time & first value
How long it actually takes to get something useful out of BenevolentAI — broken out by persona, not the marketing-page minute.
Expect weeks, not hours. Onboarding includes custom data integration and ontology alignment to your therapeutic areas, so plan for internal engineering and informatics time before first value. Qor engagements for executives and consultancies follow the vendor's own scoping. Confirm the timeline with BenevolentAI directly — no public documentation of onboarding duration exists in the material
Switching to or from BenevolentAI
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From a general-purpose LLM chat workflow: move hypothesis triage onto the knowledge graph so each association arrives with supporting evidence attached
- →From a single-omics or literature-only search tool: consolidate disease, gene and compound lookups into one graph traversal with multi-omics context
- →From internal spreadsheet target trackers: stand up graph-derived evidence alongside existing prioritisation records rather than replacing them at once
- ↗To Schrödinger: if your bottleneck is physics-based modelling and compound design rather than target identification, shift compute-heavy work there
- ↗To Recursion Pharmaceuticals: if you want a partner-led, data-generation-heavy discovery programme instead of a licensed intelligence platform
Tutorials & Learning
YouTube returned 6 videos for “BenevolentAI”, and we withheld 6: 6 could not be judged, because “BenevolentAI” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about BenevolentAI.
Official links
What are the best BenevolentAI alternatives?
The closest alternatives to BenevolentAI we list are SciSpace BioMed Agent, Insitro and Insilico Medicine. Ranked by direct product-type match, not category overlap.
| Alternative | Pricing | Starts at | Last verified |
|---|---|---|---|
| SciSpace BioMed Agent | Freemium | Pricing not published | — |
| Insitro | Contact Sales | Custom pricing | — |
| Insilico Medicine | Contact Sales | Custom pricing | — |
Alternatives to BenevolentAI
View all
SciSpace BioMed Agent
SciSpace BioMed Agent runs multi-omics, variant prioritization, and drug repurposing analysis from plain-language biomedical prompts.
Insitro
AI-native drug discovery company pairing 20+ petabytes of cellular data with human genetics to find causal disease targets
Insilico Medicine
Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.
Tools that pair well with BenevolentAI
Common stack mates teams adopt alongside BenevolentAI, with the specific reason each pairing earns its keep.
SciSpace BioMed Agent
SciSpace BioMed Agent runs multi-omics, variant prioritization, and drug repurposing analysis from plain-language biomedical prompts.
Insitro
AI-native drug discovery company pairing 20+ petabytes of cellular data with human genetics to find causal disease targets
Insilico Medicine
Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.
Frequently asked questions
Categories
Topics
Used BenevolentAI? Help shape our editorial sentiment research.